| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 07/24/2003 | CA2474002A1 Bispecific antibody dna constructs for intramuscular administration |
| 07/24/2003 | CA2473570A1 Antisense compounds directed against human csf-1 |
| 07/24/2003 | CA2472203A1 The use of il6r/il6 chimera in nerve cell regeneration |
| 07/24/2003 | CA2472170A1 Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression |
| 07/24/2003 | CA2471891A1 Methods of inducing or enhancing connective tissue repair |
| 07/24/2003 | CA2471480A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 07/24/2003 | CA2470359A1 Assay for the detection of factors that modulate the expression of ingap |
| 07/24/2003 | CA2464131A1 Compositions and methods for controlled release |
| 07/23/2003 | EP1329508A1 Novel g protein-coupled receptor protein and dna thereof |
| 07/23/2003 | EP1329504A1 Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like |
| 07/23/2003 | EP1329499A2 Growth factor-responsive progenitor cells which can be proliferated in vitro |
| 07/23/2003 | EP1328816A2 Regulation of neutral development by daedalos |
| 07/23/2003 | EP1328807A2 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain |
| 07/23/2003 | EP1328662A2 Flea peritrophin nucleic acid molecules, proteins and uses thereof |
| 07/23/2003 | EP1328653A2 Highly expressible genes |
| 07/23/2003 | EP1328646A2 Regulation of human adenylate cyclase, type iv |
| 07/23/2003 | EP1328641A2 Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof |
| 07/23/2003 | EP1328637A2 Regulation of human secretin receptor-like gpcr |
| 07/23/2003 | EP1328633A2 Human ion channel proteins and polynucleotides encoding the same |
| 07/23/2003 | EP1328631A2 Her-2/neu fusion proteins |
| 07/23/2003 | EP1328624A2 B7-like molecules and uses thereof |
| 07/23/2003 | EP1328623A2 Human proteases and polynucleotides encoding the same |
| 07/23/2003 | EP1328545A1 Human gene critical to fertility |
| 07/23/2003 | EP1328537A1 Antisense modulation of bh3 interacting domain death agonist expression |
| 07/23/2003 | EP1328536A1 Antisense modulation of glioma-associated oncogene-1 expression |
| 07/23/2003 | EP1328298A1 Methods and compositions for modulating t cell activation and uses thereof |
| 07/23/2003 | EP1328291A2 Viruses targeted to hypoxic cells and tissues |
| 07/23/2003 | EP1328287A1 Compositions and methods for wt1 specific immunotherapy |
| 07/23/2003 | EP1328254A2 Lipid formulations for target delivery |
| 07/23/2003 | EP1328151A2 Isolated nucleic acids of the p-hyde family, p-hyde proteins, and methods of inducing susceptibility to induction of cell death in cancer |
| 07/23/2003 | EP1067969B1 Polyene macrolide derivatives, use for vectoring molecules |
| 07/23/2003 | EP1019078B1 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis |
| 07/23/2003 | EP0855919B1 Induction of mucosal immune responses by vitamin d3 and antigen-encoding dna complexe to cationic lipid |
| 07/23/2003 | EP0743958B1 Avidin-biotin immunoconjugates |
| 07/23/2003 | EP0670905B1 Recombinant viruses displaying a nonviral polypeptide on their external surface |
| 07/23/2003 | CN1431907A Method of treating hepatitis delta viral infection |
| 07/23/2003 | CN1431310A Transferring carrier of liver cancer target to ward gene introduced by acceptor of alphafetoprotein enhancement type epidermal growth factor dual controlled by transcription and transfer |
| 07/23/2003 | CN1431304A Anti blood tumorous reverse VEGF gene sequence and expression carrier of recombination eukaryon |
| 07/23/2003 | CN1115414C Virus carrier used for gene therapy |
| 07/22/2003 | US6596851 Antibody for use in the treatment of cell proliferative disorders |
| 07/22/2003 | US6596698 Localized arterial transduction of RB2/pl30 via a viral vector at the time of angioplasty drastically reduces neointimal hyperplasia and prevents restenosis |
| 07/22/2003 | US6596544 Diagnosing atherosclerosis in mammals; obtain tissue sample, incbae with oxidized phospholipid, monitor adjustment in oxidation of phospholipid, absence of adjustment indicates atherosclerosis |
| 07/22/2003 | US6596535 Adeno-associated viral vector for use as tool in the transfer of genetic information for use in the treatment of arthritis |
| 07/22/2003 | US6596534 Utilization of osteocalcin promoter to deliver therapeutic genes to tumors |
| 07/22/2003 | US6596533 Polypeptide for use in the treatment of infections and cell proliferative disorders |
| 07/22/2003 | US6596526 Furin polypeptides with improved characteristics |
| 07/22/2003 | US6596515 Insulin gene amplified from human genomic DNA by use of a pair of insulin primers and a K14 promoter gene amplified by use of a pair of K14 primers inserted together into pUChsneo |
| 07/22/2003 | US6596488 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cancer |
| 07/22/2003 | US6596270 Administering the adenoviral gene transfer vector (exogenous) encoding a gene product to a muscle and the vector is neutralized outside of the muscle by systemic neutralizing antibodies; using a chimeric coat protein for cell entry |
| 07/22/2003 | US6596269 Methods of treating chronic pain |
| 07/22/2003 | US6596262 Modulated release particles for aerosol delivery |
| 07/22/2003 | US6596206 Generation of pharmaceutical agent particles using focused acoustic energy |
| 07/22/2003 | CA2109320C Peptide nucleic acids |
| 07/18/2003 | CA2369985A1 Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach |
| 07/17/2003 | WO2003057926A1 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 07/17/2003 | WO2003057898A2 Methods and materials for modulating p2x2 |
| 07/17/2003 | WO2003057892A2 Viruses with enhanced lytic potency |
| 07/17/2003 | WO2003057888A1 Cell-specific expression/replication vector |
| 07/17/2003 | WO2003057878A1 INDUCTION OF THE FORMATION OF INSULIN-PRODUCING CELLS VIA GENE TRANSFER OF PANCREATIC β-CELL-ASSOCIATED TRANSCRIPTIONAL FACTOR |
| 07/17/2003 | WO2003057870A1 Human phosphatidic acid phosphatase type 2-like protein |
| 07/17/2003 | WO2003057869A1 Regulation of human sulfatase |
| 07/17/2003 | WO2003057854A2 Novel proteins and nucleic acids encoding same |
| 07/17/2003 | WO2003057849A2 Telomere-encoding synthetic dna nanocircles, and their use for the elongation of telomere repeats |
| 07/17/2003 | WO2003057846A2 Methods and materials for modulating task-3 |
| 07/17/2003 | WO2003057843A2 Methods and materials for modulating trpc4 |
| 07/17/2003 | WO2003057840A2 Compositions for dna mediated gene silencing |
| 07/17/2003 | WO2003057835A2 Pak5-related compositions and methods |
| 07/17/2003 | WO2003057829A2 Methods of generating multispecific, multivalent agents from vh and vl domains |
| 07/17/2003 | WO2003057827A2 Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes |
| 07/17/2003 | WO2003057729A2 Mammal prolactin variants |
| 07/17/2003 | WO2003057726A1 Cytotoxic cyplasin of the sea hare, Aplysia punctata, cDNA cloning and expression of bioreactive recombinants |
| 07/17/2003 | WO2003057252A1 Human mast cell-expressed membrane proteins |
| 07/17/2003 | WO2003057190A1 Efficient nucleic acid encapsulation into medium sized liposomes |
| 07/17/2003 | WO2003057164A2 Compounds for delivering substances into cells |
| 07/17/2003 | WO2003057159A2 Psoriasin expression by breast epithelial cells |
| 07/17/2003 | WO2003057148A2 Use of biomolecular targets in the treatment and visualization of tumors |
| 07/17/2003 | WO2003057007A2 System for monitoring bacterial tumor treatment |
| 07/17/2003 | WO2003056913A1 Nonhuman model animal lacking the ability to control lymphocyte migration |
| 07/17/2003 | WO2003038057A3 Genetic vaccine against human immunodeficiency virus |
| 07/17/2003 | WO2003030827A3 Compositions for and methods of treating and preventing sirs/sepsis |
| 07/17/2003 | WO2003000896A3 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 07/17/2003 | WO2002099044A3 B3galts as modifiers of the p53 pathway and methods of use |
| 07/17/2003 | WO2002083928A3 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer |
| 07/17/2003 | WO2002081646A3 Epitope sequences |
| 07/17/2003 | WO2002058323A3 Method for identifying modulators of bace |
| 07/17/2003 | WO2002055693A3 Method for inhibiting the expression of a target gene |
| 07/17/2003 | WO2002040715A3 Molecules for disease detection and treatment |
| 07/17/2003 | WO2002039947A3 Carrier vectors through an epithelium with tight junctions |
| 07/17/2003 | WO2002017858A9 Role of fosb in bone formation |
| 07/17/2003 | WO2002006479A3 Apoptosis-inducing dna sequences |
| 07/17/2003 | US20030135873 Transgenic animal model coding fusion protein comprising nuclear protein and herpes viral vp16 protein; antidiabetic agents; uncoupling proteins |
| 07/17/2003 | US20030134819 Recombinant bacterial cells for delivery of PNP to tumor cells |
| 07/17/2003 | US20030134818 Lyophilizable and enhanced compacted nucleic acids |
| 07/17/2003 | US20030134817 SIV derived lentiviral vector systems |
| 07/17/2003 | US20030134815 Adenovirus mediated transfer of genes to the gastrointestinal tract. In particular, the present invention relates to a method of recombinant, replication-deficient adenovirus mediated transfer of therapuetic genes to the |
| 07/17/2003 | US20030134812 Bladder and lower urinary tract syndromes, particularly, irrative symptoms, and to a method of treating same using alpha 1d-adrenergic receptor ( alpha 1dAR) antagonists. The invention further relates to a method of screening compounds |
| 07/17/2003 | US20030134811 Methods and compositions comprising hydroxyapatite useful for the administration of therapeutic agents |
| 07/17/2003 | US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as |
| 07/17/2003 | US20030134785 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 07/17/2003 | US20030134430 Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides |